



CATALYZING DEVELOPMENT AND USE OF NOVEL ALTERNATIVE METHODS

August 21, 2023 (all times ET)
(<https://videocast.nih.gov/watch=49776>)

DRAFT AGENDA

9:00 AM Welcome

[Howard Chang, MD, PhD](#) & [Lyric Jorgenson, PhD](#) – ACD NAMs Working Group Co-Chairs

9:15 AM The Opportunities and Challenges for NAMs in Biomedical Research

Successful deployment of NAMs, whether for conducting basic research, uncovering disease mechanisms, or translating knowledge into products or practice, relies on bringing together disciplines, technologies, and data. This session focuses on research areas for which NAMs have been impactful to identify best practices for leveraging these approaches.

Moderator: [Nancy Lane, MD](#) – ACD NAMs Working Group

Presenters:

- [Nathan Price, PhD](#) – Thorne HealthTech (*novel mechanisms*)
- [Thomas Hartung, MD](#) – John Hopkins University (*translation/product development*)
- [Nicole Kleinstreuer, PhD](#) – U.S. National Institutes of Health (*regulatory processes*)
- [Chirag Patel, PhD](#) – Harvard Medical School (*inter-individual differences*)

10:30 AM BREAK

10:45 AM Cross Sector Approaches for Driving NAMs Use and Development

Each sector within the biomedical research enterprise has a role to play in catalyzing the development and use of NAMs. This session focuses on the unique and complementary efforts underway to identify synergies and potential gaps in needed collaboration.

Moderator: [Danilo Tagle, PhD](#) – ACD NAMs Working Group

Presenters:

- [Alex Carlisle, PhD](#) – National Alliance Against Disparities in Patient Health (*nonprofit*)
- [Elijah Petersen, PhD](#) – U.S. National Institute of Standards and Technology (*government*)
- [Yvette Seger, PhD](#) – Federation of American Societies for Experimental Biology (*scientific society*)

12:00 PM BREAK

DISCUSSION OF HIGH PRIORITY NEEDS

The following sessions focus on identifying potential high priority needs for catalyzing NAMs use and development with human applicability to (1) advance progress into understanding specific biological processes or states or (2) augment the tools and capabilities for biomedical research to complement and/or potentially replace traditional models. Specific goals will include identifying incentives for integrating efforts and barriers to success.

1:00 PM Developing Integrated and Multi-System Models

Moderator: [Szczepan Baran, VMD](#) – ACD NAMs Working Group

Discussants:

- [Graça Almeida-Porada, MD, PhD](#) – Wake Forest University
- [Blanca Rodriguez, PhD](#) – University of Oxford
- [Roser Vento-Tormo, PhD](#) – Wellcome Sanger Institute
- [Terry Van Vleet, PhD](#) – AbbVie

2:00 PM BREAK

2:15 PM Leveraging Diverse Datasets for Maximally Useful NAMs

Moderator: [Gordana Vunjak-Novakovic, PhD](#) – ACD NAMs Working Group

Discussants:

- [John Burke, PhD](#) – Applied Biomath
- [Anne Gourmelon](#) – Organisation for Economic Co-operation and Development
- [Donna Mendrick, PhD](#) – U.S. Food and Drug Administration
- [Ivan Rusyn, MD, PhD](#) – Texas A&M University
- [James Zou, PhD](#) – Stanford University

3:15 PM BREAK

3:30 PM Equitably Deploying Robust and Reliable NAMs into Practice

Moderator: [Antonio Baines, PhD](#) – ACD NAMs Working Group

Discussants:

- [Jessie Carder](#) U.S. Department of Agriculture, Animal Welfare Information Center
- [Megan LaFollette, PhD](#) – The 3Rs Collaborative
- [Michael Moore, PhD](#) – Tulane University; AxoSim
- [Manu Platt, PhD](#) – U.S. National Institutes of Health
- [Nicholas Tatonetti, PhD](#) – Columbia University

4:30 PM DISCUSSION AND NEXT STEPS

[Howard Chang, MD, PhD](#) & [Lyric Jorgenson, PhD](#) – ACD NAMs Working Group Co-Chairs

5:00 PM ADJOURN